Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency | Zendy

Adina F. Turcu | Zendy; Joanna L. Spencer-Segal | Zendy; Robert Farber | Zendy; Rosa Luo | Zendy; Dimitri E. Grigoriadis | Zendy; Carole A. Ramm | Zendy; David Madrigal | Zendy; Tim Muth | Zendy; Christopher O’Brien | Zendy; Richard J. Auchus | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency

Author(s) -

Adina F. Turcu,

Joanna L. Spencer-Segal,

Robert Farber,

Rosa Luo,

Dimitri E. Grigoriadis,

Carole A. Ramm,

David Madrigal,

Tim Muth,

Christopher O’Brien,

Richard J. Auchus

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-3574

Subject(s) - tolerability , medicine , placebo , cosyntropin , endocrinology , context (archaeology) , adrenocorticotropic hormone , antagonist , dosing , gastroenterology , receptor , urology , hormone , adverse effect , biology , paleontology , alternative medicine , pathology

Treatment of 21-hydroxylase deficiency (21OHD) is difficult to optimize. Normalization of excessive ACTH and adrenal steroid production commonly requires supraphysiologic doses of glucocorticoids.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research